SCHEMBL3814770

SCHEMBL3814770

CN(C)C(=O)c1ccc(Cl)cc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.59
HPGD P15428 3/20 0.50
HTT P42858 1/20 0.50
ALDH1A1 P00352 8/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 2/20 0.48
GAA P10253 1/20 0.47
FLT1 P17948 1/20 0.46
FLT4 P35916 1/20 0.46
KDR P35968 1/20 0.46
KDM4E B2RXH2 2/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
ALOX15 P16050 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP3A4 P08684 2/20 0.44
ALOX12 P18054 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504203 0.85 HPGD (0.54) ABL1HPGDHTTALDH1A1KMT2A
SCHEMBL3814352 0.83 HPGD (0.51) ABL1HPGDHTTALDH1A1KMT2A
SCHEMBL3816273 0.83 ABL1 (0.53) ABL1HPGDALDH1A1KMT2AMAPT
SCHEMBL5618068 0.83 ABL1 (0.61) ABL1HPGDALDH1A1KMT2AMAPT
SCHEMBL3780795 0.82 HPGD (0.58) HPGDHTTALDH1A1KMT2AMAPT
SCHEMBL9653150 0.81 ALDH1A1 (0.60) HPGDHTTALDH1A1KMT2AMAPT
SCHEMBL3816535 0.81 ABL1 (0.54) ABL1HPGDALDH1A1KMT2AMAPT
SCHEMBL3807311 0.80 ABL1 (0.50) ABL1HPGDALDH1A1KMT2AMAPT
SCHEMBL1004845 0.79 ALDH1A1 (0.45) HTTALDH1A1KMT2AMAPTMEN1
SCHEMBL824683 0.79 HPGD (0.51) HPGDHTTALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180487-B2 Substituted cyanoindoline derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-11-23 US disclosed
US-20210087182-A1 NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-03-25 US disclosed
WO-2015004481-A1 IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS) ASTEX THERAPEUTICS LIMITED (GB) 2015-01-15 WO disclosed
WO-2015004481-A1 IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS) ASTEX THERAPEUTICS LIMITED (GB) 2015-01-15 WO disclosed
US-7524855-B2 Selected benzofuran derivatives ARPIDA AG (CH) 2009-04-28 US disclosed
US-20080108610-A1 Selected Benzofuran Derivatives ARPIDA AG (CH) 2008-05-08 US disclosed
EP-1838704-A1 SELECTED BENZOFURAN DERIVATIVES Arpida AG (CH) 2007-10-03 EP disclosed
WO-2006072370-A1 SELECTED BENZOFURAN DERIVATIVES ARPIDA AG (CH) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108610-A1 Selected Benzofuran Derivatives ABCG2, BPTF, SBDS ABL1 866/4885HPGD 311/4885HTT 2085/4885
US-20210087182-A1 NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS NFKBIA, IKBKG, IKBKB ABL1 877/4885HPGD 1127/4885HTT 4168/4885
US-11180487-B2 Substituted cyanoindoline derivatives as NIK inhibitors NFKBIA, MAP3K14, IKBKG ABL1 691/4885HPGD 881/4885HTT 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.